Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma

Lenalidomide is considered a standard of care in multiple myeloma (MM) Some MM patients will develop delayed hypersensitivity to lenalidomide, which can lead to treatment discontinuation. Desensitization to lenalidomide can help these patients to complete treatment courses. Here, we aimed to review lenalidomide‐treated MM patients who developed delayed hypersensitivity‐induced rash and were treated with desensitization.

[1]  J. Bernstein,et al.  Drug Allergy: A 2022 Practice Parameter Update. , 2022, The Journal of allergy and clinical immunology.

[2]  A. Lesokhin,et al.  Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma , 2022, Leukemia & lymphoma.

[3]  T. Uchida,et al.  Simple desensitization protocol for multiple myeloma patients with lenalidomide‐induced skin rash: Case series , 2021, Journal of clinical pharmacy and therapeutics.

[4]  T. Uchida,et al.  Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma , 2021, Leukemia & lymphoma.

[5]  A. Fiandor,et al.  Successful desensitization procedure to lenalidomide in a patient with delayed hypersensitivity confirmed with a positive LTT. , 2020, European annals of allergy and clinical immunology.

[6]  Ş. Beyaz,et al.  A practical 16-day Desensitization Protocol in Lenalidomide induced Non-immediate Hypersensitivity Reactions. , 2019, Annals of Allergy, Asthma & Immunology.

[7]  P. Neri,et al.  Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center , 2019, Leukemia & lymphoma.

[8]  N. Agmon-Levin,et al.  Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity—a multicenter experience , 2018, Lupus.

[9]  B. Ebert,et al.  The novel mechanism of lenalidomide activity. , 2015, Blood.

[10]  S. Kurtin,et al.  Practical Management of Lenalidomide-Related Rash. , 2015, Clinical lymphoma, myeloma & leukemia.

[11]  Paige G. Wickner,et al.  Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma , 2014, British journal of haematology.

[12]  D. West,et al.  Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. , 2013, Clinical Lymphoma, Myeloma & Leukemia.

[13]  P. Demoly,et al.  Desensitization in delayed drug hypersensitivity reactions – an EAACI position paper of the Drug Allergy Interest Group , 2013, Allergy.

[14]  D. Reece,et al.  Desensitization to lenalidomide in a patient with relapsed multiple myeloma. , 2013, Clinical lymphoma, myeloma & leukemia.

[15]  A. Verma,et al.  Mechanism of action of lenalidomide in hematological malignancies , 2009, Journal of hematology & oncology.

[16]  A. Hindenburg,et al.  Successful desensitization in a patient with lenalidomide hypersensitivity , 2007, American journal of hematology.

[17]  A. Dispenzieri,et al.  Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. , 2006, Archives of dermatology.

[18]  M. Blaiss,et al.  Drug allergy. , 1988, Pediatric clinics of North America.